{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:27:43Z","timestamp":1721780863815},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"DOI":"10.7759\/cureus.65207","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T16:21:57Z","timestamp":1721751717000},"source":"Crossref","is-referenced-by-count":0,"title":["Diffuse Maculopapular Dermatitis Associated With Leuprorelin Acetate Androgen Deprivation Therapy"],"prefix":"10.7759","author":[{"given":"Kwabena Boahen","family":"Asare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirav S","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1557988320979257","article-title":"Prostate cancer treatment and work: a scoping review","volume":"14","author":"Yu Ko WF","year":"2020","unstructured":"Yu Ko WF, Oliffe JL, Bottorff JL. Prostate cancer treatment and work: a scoping review. Am J Mens Health. 2020, 14:1557988320979257. 10.1177\/1557988320979257","journal-title":"Am J Mens Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu S","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet. 2021, 398:1075-90. 10.1016\/S0140-6736(21)00950-8","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.03.002","article-title":"Intermediate-risk prostate cancer: stratification and management","volume":"3","author":"Preisser F","year":"2020","unstructured":"Preisser F, Cooperberg MR, Crook J, et al.. Intermediate-risk prostate cancer: stratification and management. Eur Urol Oncol. 2020, 3:270-80. 10.1016\/j.euo.2020.03.002","journal-title":"Eur Urol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/106002808602001001","article-title":"Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer","volume":"20","author":"Wojciechowski NJ","year":"1986","unstructured":"Wojciechowski NJ, Carter CA, Skoutakis VA, Bess DT, Falbe WJ, Mickle TR. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. Drug Intell Clin Pharm. 1986, 20:746-51. 10.1177\/106002808602001001","journal-title":"Drug Intell Clin Pharm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s6863","article-title":"Leuprorelin depot injection: patient considerations in the management of prostatic cancer","volume":"4","author":"Abouelfadel Z","year":"2008","unstructured":"Abouelfadel Z, Crawford ED. Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Ther Clin Risk Manag. 2008, 4:513-26. 10.2147\/tcrm.s6863","journal-title":"Ther Clin Risk Manag"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/cia.s4885","article-title":"Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer","volume":"4","author":"Sethi R","year":"2009","unstructured":"Sethi R, Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging. 2009, 4:259-67. 10.2147\/cia.s4885","journal-title":"Clin Interv Aging"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.100941","article-title":"Addition of enzalutamide to leuprolide and definitive radiation therapy is tolerable and effective in high-risk localized or regional nonmetastatic prostate cancer: results from a phase 2 trial","volume":"7","author":"Shee K","year":"2022","unstructured":"Shee K, de la Calle CM, Chang AJ, et al.. Addition of enzalutamide to leuprolide and definitive radiation therapy is tolerable and effective in high-risk localized or regional nonmetastatic prostate cancer: results from a phase 2 trial. Adv Radiat Oncol. 2022, 7:100941. 10.1016\/j.adro.2022.100941","journal-title":"Adv Radiat Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2016.06.005","article-title":"Testosterone therapy among prostate cancer survivors","volume":"4","author":"Nguyen TM","year":"2016","unstructured":"Nguyen TM, Pastuszak AW. Testosterone therapy among prostate cancer survivors. Sex Med Rev. 2016, 4:376-88. 10.1016\/j.sxmr.2016.06.005","journal-title":"Sex Med Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-016-1110-5","article-title":"Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report","volume":"10","author":"Chang JI","year":"2016","unstructured":"Chang JI, Bucci J. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report. J Med Case Rep. 2016, 10:323. 10.1186\/s13256-016-1110-5","journal-title":"J Med Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2014.19.3.135","article-title":"Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty","volume":"19","author":"Lee JW","year":"2014","unstructured":"Lee JW, Kim HJ, Choe YM, Kang HS, Kim SK, Jun YH, Lee JE. Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty. Ann Pediatr Endocrinol Metab. 2014, 19:135-40. 10.6065\/apem.2014.19.3.135","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"ref11","article-title":"Leuprolide acetate-induced generalized papular eruption","volume":"13","author":"Burris K","year":"2014","unstructured":"Burris K, Ding CY, Lim GF. Leuprolide acetate-induced generalized papular eruption. J Drugs Dermatol. 2014, 13:755-7.","journal-title":"J Drugs Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16176","article-title":"Papuloerythroderma-like eruptions after leuprolide acetate injections in a middle-aged woman","volume":"61","author":"Katsuo K","year":"2022","unstructured":"Katsuo K, Yagi Y, Kuwai T, Yoshida Y, Okoshi T, Tajima K. Papuloerythroderma-like eruptions after leuprolide acetate injections in a middle-aged woman. Int J Dermatol. 2022, 61:e431-3. 10.1111\/ijd.16176","journal-title":"Int J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/00016340600608717","article-title":"Leuprolide acetate-induced leukocytoclastic vasculitis","volume":"86","author":"Turk BG","year":"2007","unstructured":"Turk BG, Dereli T, Dereli D, Akalin T. Leuprolide acetate-induced leukocytoclastic vasculitis. Acta Obstet Gynecol Scand. 2007, 86:892-3. 10.1080\/00016340600608717","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.8112","article-title":"Case - leuprolide acetate-induced necrotic skin ulceration","volume":"17","author":"Ian Janes WC","year":"2023","unstructured":"Ian Janes WC, Ogunyemi B, Andrews M. Case - leuprolide acetate-induced necrotic skin ulceration. Can Urol Assoc J. 2023, 17:E92-4. 10.5489\/cuaj.8112","journal-title":"Can Urol Assoc J"},{"key":"ref15","article-title":"Leuprolide acetate-induced dermatitis herpetiformis","volume":"75","author":"Grimwood RE","year":"2005","unstructured":"Grimwood RE, Guevara A. Leuprolide acetate-induced dermatitis herpetiformis. Cutis. 2005, 75:49-52.","journal-title":"Cutis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.08.024","article-title":"Dermatitis herpetiformis associated with administration of a gonadotropin-releasing hormone analog","volume":"54","author":"Yu SS","year":"2006","unstructured":"Yu SS, Connolly MK, Berger TG, McCalmont TH. Dermatitis herpetiformis associated with administration of a gonadotropin-releasing hormone analog. J Am Acad Dermatol. 2006, 54:S58-9. 10.1016\/j.jaad.2005.08.024","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2009.01643.x","article-title":"Systemic allergic dermatitis caused by the solvent of Eligard","volume":"61","author":"Ruiz-Hornillos J","year":"2009","unstructured":"Ruiz-Hornillos J, Henr\u00edquez-Santana A, Moreno-Fern\u00e1ndez A, Gonz\u00e1lez IG, S\u00e1nchez SR. Systemic allergic dermatitis caused by the solvent of Eligard. Contact Dermatitis. 2009, 61:355-6. 10.1111\/j.1600-0536.2009.01643.x","journal-title":"Contact Dermatitis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2008.0502","article-title":"Disseminated maculopapular eruption caused by leuprorelin acetate","volume":"18","author":"Sugita K","year":"2008","unstructured":"Sugita K, Kabashima K, Tokura Y. Disseminated maculopapular eruption caused by leuprorelin acetate. Eur J Dermatol. 2008, 18:603-4. 10.1684\/ejd.2008.0502","journal-title":"Eur J Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2012.01980.x","article-title":"Follicular mucinosis and mycosis-fungoides-like drug eruption due to leuprolide acetate: a case report and review","volume":"39","author":"Shalin SC","year":"2012","unstructured":"Shalin SC, Brantley J, Diwan AH. Follicular mucinosis and mycosis-fungoides-like drug eruption due to leuprolide acetate: a case report and review. J Cutan Pathol. 2012, 39:1022-5. 10.1111\/j.1600-0560.2012.01980.x","journal-title":"J Cutan Pathol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0712","article-title":"Drug-induced papuloerythroderma: analysis of T-cell populations and a literature review","volume":"89","author":"Sugita K","year":"2009","unstructured":"Sugita K, Kabashima K, Nakamura M, Tokura Y. Drug-induced papuloerythroderma: analysis of T-cell populations and a literature review. Acta Derm Venereol. 2009, 89:618-22. 10.2340\/00015555-0712","journal-title":"Acta Derm Venereol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/274207-diffuse-maculopapular-dermatitis-associated-with-leuprorelin-acetate-androgen-deprivation-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T16:22:01Z","timestamp":1721751721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/274207-diffuse-maculopapular-dermatitis-associated-with-leuprorelin-acetate-androgen-deprivation-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.65207","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}